Prevalence of asymptomatic nephrolithiasis amongst prospective living kidney donors
DOI:
https://doi.org/10.18203/2349-2902.isj20241732Keywords:
Nephrolithiasis, Asymptomatic, Donors, KidneyAbstract
Background: About 12% of men and 5% of women will develop symptomatic nephrolithiasis during their lifetime. Symptomatic nephrolithiasis is linked to many systemic conditions such as metabolic syndrome, chronic kidney disease and hyperparathyroidism. Not much is known about the prevalence of nephrolithiasis in asymptomatic patients as well as their association with systemic conditions seen in the symptomatic subset.
Methods: This is a retrospective study of all prospective living kidney donors who presented to Zenith Medical and Kidney Centre, Abuja, Nigeria between January 2022 and December 2022. Relevant information was retrieved from the institution’s computer database, entered in a structured proforma and analyzed with SPSS version 25.0. Results were reported in percentages, mean±standard deviation.
Results: A total of 133 patients were recruited for the study, the age range was 18-52 years with mean age of 27.47 years and standard deviation of 6.8. The male to female ratio was 15.6:1. The body mass was greater than 30 kg/m2 in 4.8% of patients. Hypertension was found in 5.3% while urinary tract infection was found in 24.1% of the patients. Nephrolithiasis was seen in 5.3% of the patients, with size ranging from 2.14mm to 9.4mm, the stone was bilateral in 0.8% of the patients.
Conclusions: The prevalence of asymptomatic nephrolithiasis amongst prospective kidney donors is 5.3%. Asymptomatic kidney stone formers have different demographic characteristics and lack the co-morbidities described in symptomatic kidney stone formers.
Metrics
References
Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63:1817-23.
Soucie JM, Coates RJ, McClellan W, Austin H, Thin M. Relationship between geographic variability in kidney stones prevalence and risk factors for stones. Am J Epidemiol. 1996;143:487-95.
D’Angelo A, Calo’ L, Cantaro S, Giannini S. Calcitropic hormones and nephrolithiasis. Miner Electrolyte Metab. 1997;23:269-72.
Parks J, Coe F, Favus M. Hyperparathyroidism in nephrolithiasis. Arch Intern Med. 1980;140:1479-81.
Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68:1230-5.
Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ. Body size and risk of kidney stones. J AM Soc Nephrol. 1998;9:1645-52.
Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293:455-62.
Abate N, Chandalia M, Cabo-chan AV, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65:386-92.
Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K. Low urine PH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol. 2007;2:883-8.
West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H. Metabolic syndrome and self reported history of kidney stones: The National health and nutrition Examination survey(NHANES 111) 1988- 1994. Am J Kidney Dis. 2008;51:741-7.
Cappuccio FP, Strazzullo P, Mancini M. Kidney stones and hypertension: population based study of an independent clinical association. BMJ. 1990;300:1234-6.
Madore F, Stampfer MJ, Rimm EB, Curhan GC. Nephrolithiasis and risk of hypertension. Am J Hypertens. 1998;11:46-53.
Madore F, Stampfer MJ, Willett WC, Speizer FE, Curhan GC. Nephrolithiasis and risk of hypertension in women. Am J Kidney Dis 1998;32:802-7.
Sinha MK, Collazo-Clavell ML, Rule A, Milliner DS, Nelson W, Sarr MG, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-y gastric bypass surgery. Kidney Int. 2007;72:100-7.
Gillen DL, Worlester EM, Coe FL. Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES 111. Kidney Int. 2005;67:685-90.
Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis. 2004;44:799-805.
Rule AD, Bergstralh EJ, Melton LJ, Li X, Weaver AL, Lieske JC. Kidney stones and the risk of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:804-11.
Vupputuri S, Soucie MJ, McClellan W, Sandler DP. History of kidney stones as a possible risk factor for chronic kidney disease. Ann Epidemiol. 2004;14:222-8.
Worlester EM, Parks JH, Evan AP, Coe FL. Renal function in patients with nephrolithiasis. J Urol. 2006;176:600-3.
Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone diseases in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22:513-9.
Varanelli MJ, Coll DM, Levine JA, Rosenfield AT, Smith RC. Relationship between duration of pain and secondary signs of obstruction of the urinary tract on unenhanced helical CT. AJR Am J Roentgenol. 2001;177:325-30.
Parks JH, Coe FL, Strauss AL. Calcium nephrolithiasis and medullary sponge kidney in women. N Engl J Med. 1982;306:1088-91.
Yagisawa T, Kobayashi C, Hayashi T, Yoshida A, Toma H. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney. Am J Kidney Dis. 2001;37:1140-3.
Lorenz EC, Vrtiska TJ, Lieske JC, Dillon JJ, Stegall MD,Li Xujian, et al. Prevalence of renal artery and kidney abnormalities by computed tomography among healthy adults. Clin J Am Soc Nephrol. 2010;5:431-8.
Parks JH, Coe FL, Evan AP, Worcester EM. Clinical and laboratory characteristics of calcium stone formers with and without primary hyperparathyroidism. BJU Int. 2009;103:670-8.
Younes NA, Shafagoj Y, Khatib F, Ababneh M. Laboratory Screening for hyperparathyroidism. Clin Chim Acta. 2005;353:1-12.
Downloads
Published
How to Cite
Issue
Section
